Difference between revisions of "Moclobemide-bupropion"
From Psychiatrienet
| Line 10: | Line 10: | ||
* '''Day 10:''' start bupropion after this period in a normal dosage of 150 mg/day. | * '''Day 10:''' start bupropion after this period in a normal dosage of 150 mg/day. | ||
| info = | | info = | ||
| − | * Occurrence of the serotonin syndrome is possible without a wash-out period.}} | + | * Occurrence of the serotonin syndrome is possible without a wash-out period. |
| + | |info= | ||
| + | {{review}} | ||
| + | }} | ||
Revision as of 12:14, 14 October 2015
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
Switch medication from moclobemide to bupropion.[1] [2]
Stop moclobemide - Before day 1: gradually reduce dosage of moclobemide to a maximum of 300 mg/day.
- Day 1: reduce the dosage of moclobemide to 150 mg/day.
- Day 8: stop administration of moclobemide.
Start bupropion- Day 8-9: a wash-out period of two days is necessary.
- Day 10: start bupropion after this period in a normal dosage of 150 mg/day.
More information- This switch is currently being reviewed.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
